The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, Dr. William Oh speaks with Ewen Ward, Dr. Daniel Chen, and Dr. Greg Thurber about the evolving science of antibody-drug conjugates. They discuss how ADCs combine antibody targeting with potent payloads, why linker stability and tumor distribution matter, how ADCs may interact with the immune system, and what next-generation formats could mean for future cancer care. Listen now on all major platforms!

“The ultimate goal is to improve both the durability of responses and the quality of life for patients receiving ADC-based cancer therapies.” - Dr. Greg Thurber

Meet the guests:

Ewen Ward is Program Director for the World ADC Event Series at Hanson Wade. He works closely with the global ADC community, conducting market research and translating insights into scientific agendas and speaker programs for World ADC conferences in London and San Diego. His role focuses on connecting researchers, clinicians, and industry professionals to highlight key trends, challenges, and innovations shaping ADC development.

Dr. Daniel Chen is a physician scientist, pioneer in cancer immunotherapy and protein engineering, and co-author of the Cancer Immunity Cycle. He spent over a decade at Genentech as Vice President and Global Head of Cancer Immunotherapy Development, leading the development of immune therapies, ADCs, targeted treatments, and diagnostic strategies. He led the clinical development of atezolizumab from preclinical studies through commercialization. He is Founder & CEO of Synthetic Design Lab and Founding Partner of Genesis BioCapital, focused on next-generation engineered therapeutics.

Dr. Greg Thurber is Professor of Chemical Engineering and Biomedical Engineering at the University of Michigan. His research focuses on quantitative pharmacology, drug distribution, and predictive models for cancer therapies. His laboratory uses in vivo microscopy and mathematical simulations to understand how therapeutic molecules, including small molecules, peptides, antibodies, and ADCs, move through the body. His work aims to improve cancer treatment design, efficacy, and safety.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (01:29) Introduction
• (04:09) Defining ADCs
• (10:30) Chemotherapy delivery
• (15:14) ADC innovation
• (21:40) World ADC San Diego conference
• (24:37) Future ADC innovation
• (32:50) Closing thoughts

The Oncology Insights Podcast is trusted and supported by innovative companies like:

Hanson Wade, ADC San Diego

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

YouTube: The Oncology Insights Podcast

Facebook: The Oncology Insights Podcast

TikTok: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Dr. Timothy Burns, Professor of Medicine at The Ohio State University, about KRAS inhibitors within the evolving spectrum of systemic therapies for Non-Small Cell Lung Cancer (NSCLC). We discuss KRAS mutations, treatment resistance, immunotherapy combinations, biomarker testing, brain metastases, and his journey into lung cancer research. Listen now on all major platforms!

“KRAS mutations represent a major therapeutic target across cancers, creating opportunities for increasingly selective inhibitors designed around specific molecular alterations.”

Meet the guest: Dr. Timothy Burns is Professor of Medicine at The Ohio State University Comprehensive Cancer Center. With more than 89 publications and NCI R01 funding, his research advances targeted therapies for oncogene-driven NSCLC and brain metastases. He has led multiple clinical trials, including early-phase studies contributing to the approval of the KRAS G12C inhibitor sotorasib. Listen to Dr. Timothy Burns on The Oncology Insights Podcast, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (01:50) Introduction
• (07:30) Targeting KRAS mutations
• (11:30) Resistance mechanisms
• (15:04) Therapy combinations
• (20:50) Brain metastases
• (28:53) Future KRAS strategies
• (36:17) Closing thoughts

The Oncology Insights Podcast is trusted and supported by innovative companies like:

- WiseVAs

- Elevate

- Zentrix Insights

- ZentrixOS

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

YouTube: The Oncology Insights Podcast

Facebook: The Oncology Insights Podcast

TikTok: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Dr. Michael Hofman, a nuclear medicine physician and professor at Peter MacCallum Cancer Centre, about the evolution of theranostics and targeted radiopharmaceutical therapy. We examine radioactive iodine, PSMA PET imaging, lutetium 177 therapy, prostate cancer applications, and opportunities to expand these approaches across oncology. Listen now on all major platforms!

“Lutetium 177 delivers targeted radiation over a short distance after binding to tumor cells, helping limit radiation exposure across most normal tissues.”

Meet the guest: Dr. Michael Hofman is a nuclear medicine physician and professor at Peter MacCallum Cancer Centre whose research focuses on PSMA PET imaging, radioligand therapy, and prostate cancer. He has led multicenter clinical trials supporting advances in targeted cancer imaging and treatment, published more than 300 papers, and secured substantial research funding. Listen to Dr. Michael Hofman on The Oncology Insights Podcast, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (01:34) Introduction
• (08:15) Theranostic imaging
• (17:49) Targeted radiation
• (23:46) PSMA development
• (26:46) PSMA imaging
• (28:15) Prostate therapy
• (31:15) Final Questions

The Oncology Insights Podcast is trusted and supported by innovative companies like:

- ZentrixOS

- Zentrix Insights

- Elevate

- WiseVAs

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

YouTube: The Oncology Insights Podcast

Facebook: The Oncology Insights Podcast

TikTok: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, Dr. Maximilian Stahl, Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, explains how acute myeloid leukemia care is becoming more precise. He discusses molecular testing, induction therapy selection, targeted agents, transplant decisions, APL advances, and early phase trials for high-risk AML. Listen now on all major platforms!

"Molecular genetics now guide AML treatment selection, helping clinicians choose the best first therapy instead of simply starting the fastest regimen."

Meet the guest: Dr. Maximilian Stahl is Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center and Assistant Professor of Medicine at Yale School of Medicine. His work focuses on acute leukemia, early phase clinical trials, targeted therapy, measurable residual disease, and drug development for high-risk AML. Learn more from Dr. Maximilian Stahl on The Oncology Insights Podcast, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (01:47) Introduction
• (06:48) AML testing
• (12:03) Transplant choices
• (17:49) Maintenance therapy
• (23:27) MRD monitoring
• (29:51) GVHD advances
• (40:03) Closing thoughts

The Oncology Insights Podcast is trusted and supported by innovative companies like:

- Elevate

- WiseVAs

- ZentrixOS

- Zentrix Insights

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

YouTube: The Oncology Insights Podcast

Facebook: The Oncology Insights Podcast

TikTok: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Dr. Xiuning Le, Associate Professor and Section Chief at The University of Texas MD Anderson Cancer Center, about the evolution of precision medicine in lung cancer. We discuss actionable mutations, targeted therapies, immunotherapy, early detection strategies, brain metastases, and emerging innovations shaping the future of oncology care. Listen now on all major platforms!

"Targeted therapies are developed by understanding which oncogenic pathways drive tumor growth and identifying methods to overcome treatment resistance."

Meet the guest: Dr. Xiuning Le is a tenured Associate Professor and Section Chief in Thoracic and Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. Her research focuses on oncogene driven non small cell lung cancer, targeted therapies, brain metastases, and translational oncology. She has led clinical trials that contributed to new standards of care and FDA approvals. Listen to Dr. Xiuning Le on The Oncology Insights Podcast, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:52) Introduction
• (05:38) Precision oncology
• (12:27) Actionable mutations
• (19:38) Immunotherapy biomarkers
• (25:14) Early detection
• (29:11) Brain metastases
• (32:20) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

YouTube: The Oncology Insights Podcast

Facebook: The Oncology Insights Podcast

TikTok: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Dr. Michael Postow, Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, about how immunotherapy transformed melanoma care. Dr. Postow explores checkpoint inhibitors, combination strategies, biomarkers, and emerging approaches like cell therapies and personalized cancer vaccines. He explains patient outcomes, risks, and future innovations shaping oncology. Listen now on all major platforms!

"Immune checkpoint inhibitors work by enhancing T cell activity, carefully adjusting immune response intensity to improve cancer control without triggering excessive autoimmune complications."

Meet the guest: Dr. Michael Postow is Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, specializing in immunotherapy and advanced melanoma research. His work focuses on checkpoint inhibitors, clinical trials, and innovative treatment strategies to improve patient outcomes. He continues to advance precision oncology and mentor future leaders in cancer care. Listen to Dr. Michael Postow on The Oncology Insights Podcast, available on all major platforms!

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (01:02) Introduction
• (03:59) Immunotherapy basics
• (05:08) Checkpoint combinations
• (07:39) Side effects risks
• (10:11) Biomarker challenges
• (16:04) Future therapies
• (29:34) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Dr. Wade Swenson, medical oncologist at Lakewood Health System and founder of the Rural Cancer Institute, about the challenges of delivering cancer care in underserved rural communities. He explores the rural cancer gap, social determinants of health, screening barriers, and the role of policy and workforce development. Dr. Swenson also highlights innovative models for decentralizing care while maintaining quality standards. Listen now on all major platforms!

"Lung cancer accounts for a large portion of the rural cancer mortality gap, highlighting the need for improved screening and early detection strategies."

Meet the guest: Dr. Wade Swenson is a medical oncologist specializing in rural cancer care delivery and founder of the Rural Cancer Institute. He serves at Lakewood Health System and holds academic roles at TCU and the University of North Dakota. His work focuses on reducing disparities, improving access, and advancing oncology workforce development in underserved regions. 

Read the full research articles:

Kava, Christine M., et al. "Differences in lung cancer death rates by rural vs. urban status in comparison to all-cancer death rates—United States, 1999–2020." Cancer epidemiology 95 (2025): 102763.

Walker, Margaret R., et al. "Challenges and Opportunities for Rural Multidisciplinary Lung Cancer Care." Journal of the American College of Radiology 22.12 (2025): 1609-1617.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:51) Introduction
• (05:55) Rural disparities
• (07:19) Social determinants
• (06:11) Care models
• (18:43) Screening barriers
• (24:25) Policy advocacy
• (35:16) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Dr. Lisa Carter-Bawa, Director of the Cancer Prevention Precision Control Institute at Hackensack Meridian Health, about how stigma, trust, and communication shape cancer prevention and early detection. Dr. Carter-Bawa explores lung cancer screening, patient engagement, behavioral science, and the role of community-based interventions. She also examines how emerging tools such as artificial intelligence and biomarkers intersect with patient behavior and equity. Listen now on all major platforms!

"Lung cancer screening decisions are shaped by stigma and self blame in ways that are not present in many other cancer screening contexts."

Meet the guest: Dr. Lisa Carter-Bawa is a behavioral scientist and nurse practitioner whose work focuses on stigma, trust, and engagement across the cancer prevention continuum. She leads cancer prevention research at Hackensack Meridian Health and oversees community outreach at Georgetown Lombardi Comprehensive Cancer Center. Her nationally funded research advances lung cancer screening equity through patient-centered communication. 

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:29) Introduction
• (05:56) Research roles
• (10:24) Screening foundations
• (12:37) Stigma drivers
• (14:41) Awareness gaps
• (18:52) Early detection future
• (23:35) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Dr. Tony Abraham, President and Medical Director, and Daniel Varghese, CEO of RadiantPath Health, about expanding access to nuclear theranostics in oncology. They explore mobile delivery of Lu-177 PSMA therapy, regulatory and staffing barriers, and patient-centered care models, and examine how bringing advanced treatments into community settings can reduce travel burden and improve therapy completion. Daniel and Dr. Abraham also highlight the role of artificial intelligence, safety standards, and future applications beyond prostate cancer. Listen now on all major platforms!

"Theranostics allows clinicians to precisely identify cancer targets through imaging and then deliver treatment directly to those same sites, minimizing damage to surrounding healthy tissues." - Dr. Tony Abraham

Meet the guests:

Daniel Varghese is a board-certified Physician Assistant and CEO of RadiantPath Health, leading the first mobile nuclear medicine unit in the United States.

Dr. Tony Abraham is a Nuclear Medicine Physician with fellowship training in PET/CT and nuclear oncology, and over 20 years of experience advancing targeted therapeutics in cancer care.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:42) Introduction
• (07:28) Theranostics explained
• (10:11) Patient experience
• (12:10) Access limitations
• (14:51) Staffing barriers
• (22:43) Mobile scheduling
• (40:38) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Ewen Ward, Brand Director at Hanson Wade Group, about the evolution and future direction of antibody drug conjugates in oncology. Ewen explores how ADC innovation is reshaping cancer treatment, from payload design to clinical impact. He also highlights the role of global scientific collaboration through the 16th World ADC London Summit. Listen now on all major platforms!

"Antibody drug conjugates combine targeted antibodies with potent anti-cancer agents, creating therapies designed to improve precision while addressing long-standing toxicity and efficacy challenges."

Meet the guest: Ewen Ward is Brand Director at the Hanson Wade Group, where he leads the development of global scientific conferences focused on antibody-drug conjugates. With a background in biochemistry, his work centers on translating scientific challenges into impactful oncology agendas. 

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:28) Introduction
• (04:36) ADC definition
• (05:53) Toxicity challenges
• (06:51) Payload innovation
• (09:27) Clinical impact
• (11:52) Conference scope
• (31:43) Final Questions

The Oncology Insights Podcast is trusted and supported by innovative companies like:

World ADC London 2026

Beacon - Access to Life Sciences Data - Hanson Wade

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast